Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Peginterferon Alfa-2a Plus Ribavirin in Post-Renal Transplant Hepatitis C
NCT00881582Phase 4Completed
- Sponsor
- King Abdulaziz Medical City
- Start
- Jan 2009
- Primary completion
- Dec 2011
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of peginterferon alfa-2a in hepatitis C (HCV), sponsored by King Abdulaziz Medical City. Primary endpoint: Sustained Virologic Response. Started Jan 2009; status: completed.
02
Drugs
peginterferon alfa-2a
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT00881582.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00881582.